Spotlight

Feb 27, 2026

Fluid Balance in Amyloidosis: Why Too Much or Too Little Can Harm Table of Contents

From Medical School to Translational Research: Jainith Patel, M27

Feb 20, 2026

https://oneamyloidosisvoice.com/news-meeting/fda-approved-drugs-can-extend-lives-cardiac-amyloidosis-patients

Feb 20, 2026

New Study Validates ATTR-QOL as Effective Measure of Patient Burden

Feb 20, 2026

Case report: insulin derived amyloidosis in a patient with insulin dependent type 2 diabetes

Feb 19, 2026

Clinical and genetic features of hereditary transthyretin amyloidosis with polyneuropathy in China: insights from case analysis and literature review

Feb 18, 2026

FDA-approved drugs can extend lives of cardiac amyloidosis patients

Feb 13, 2026

Sean’s Patient Story: Amyloidosis

Feb 12, 2026

Tracheobronchial and Conjunctival Amyloidosis: A Rare Presentation

Feb 10, 2026

Focus Issue: Amyloid Heart Disease

Feb 10, 2026

Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis

Subscribe to

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion